Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | F12 | P00748 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | PLAT | P00750 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HPN | P05981 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14723640 | 0.88 | HDAC1 (0.57) | KMT2AGAAMAPTHTTALDH1A1 | |
| SCHEMBL16436962 | 0.85 | KMT2A (0.50) | KMT2AGAAMAPTHTTALDH1A1 | |
| SCHEMBL14723634 | 0.85 | L3MBTL1 (0.55) | KMT2AGAAMAPTHTTALDH1A1 | |
| SCHEMBL13425158 | 0.83 | PRSS1 (0.56) | KMT2AMAPTHTTALDH1A1LMNA | |
| SCHEMBL16436961 | 0.83 | KMT2A (0.55) | KMT2AMAPTHTTALDH1A1LMNA | |
| SCHEMBL17518442 | 0.81 | KMT2A (0.59) | KMT2AGAAMAPTHTTALDH1A1 | |
| SCHEMBL7995786 | 0.80 | L3MBTL1 (0.69) | KMT2AGAAMAPTHTTALDH1A1 | |
| SCHEMBL11384041 | 0.80 | KMT2A (0.60) | KMT2AGAAMAPTHTTALDH1A1 | |
| SCHEMBL14276951 | 0.79 | KMT2A (0.50) | KMT2AMAPTHTTALDH1A1LMNA | |
| SCHEMBL14276950 | 0.78 | PRSS1 (0.50) | KMT2AGAAMAPTHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190696-A1 | Pharmaceutical Formulation for Histone Deacetylase Inhibitors | MEDIVIR AB (SE) | 2023-06-22 | — | — | US | disclosed |
| US-20170360741-A1 | Pharmaceutical Formulation for Histone Deacetylase Inhibitors | MEDIVIR AB (SE) | 2017-12-21 | — | — | US | disclosed |
| US-9724321-B2 | Histone deacetylase inhibitors | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160106700-A1 | Pharmaceutical Formulation for Histone Deacetylase Inhibitors | MEDIVIR AB (SE) | 2016-04-21 | — | — | US | disclosed |
| US-9255066-B2 | Pharmaceutical formulation for histone deacetylase inhibitors | TETRALOGIC SHAPE UK LTD (GB) | 2016-02-09 | — | — | US | disclosed |
| US-9199923-B2 | Histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150038581-A1 | HISTONE DEACETYLASE INHIBITORS | Harvard University & Medical School | 2015-02-05 | — | — | US | disclosed |
| US-20130203847-A1 | Pharmaceutical Formulation for Histone Deacetylase Inhibitors | SHAPE PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-8383855-B2 | Histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190696-A1 | Pharmaceutical Formulation for Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC4 | KMT2A 50/4885GAA 82/4885MAPT 743/4885 |
| US-20170360741-A1 | Pharmaceutical Formulation for Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC4 | KMT2A 50/4885GAA 82/4885MAPT 743/4885 |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | KMT2A 83/4885GAA 537/4885MAPT 1332/4885 |
| US-20130203847-A1 | Pharmaceutical Formulation for Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC4 | KMT2A 50/4885GAA 82/4885MAPT 743/4885 |
| US-20150038581-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | KMT2A 38/4885GAA 363/4885MAPT 1317/4885 |
| US-20160106700-A1 | Pharmaceutical Formulation for Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC4 | KMT2A 50/4885GAA 82/4885MAPT 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.